Gastroduodenal mucosal defense

Current Opinion in Gastroenterology

Volumn 22, Issue 6, 2006, Pages 599-606

  Dong, Mamie H ^b   Kaunitz, Jonathan D ^a,b,c,d  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b UCLA MEDICAL CENTER   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Brentwood Biomedical Research Institute Los Angeles   (United States)

Author keywords

Annexin 1; Antioxidants; Esophagus; Ghrelin; Helicobacter pylori; Reactive oxygen species

Indexed keywords

ALENDRONIC ACID; ANETHOLE; ANTIOXIDANT; ASTAXANTHIN; BISPHOSPHONIC ACID DERIVATIVE; CARNITINE; D 002; DA 9601; DEXAMETHASONE; GHRELIN; GROWTH HORMONE; HEXARELIN; MONTELUKAST; NAPROXEN; NIGELLA SATIVA EXTRACT; NITRONAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLANT EXTRACT; REBAMIPIDE; ROFECOXIB; UNCLASSIFIED DRUG;

CLINICAL TRIAL; DRUG EFFICACY; DUODENUM; ESOPHAGITIS; GASTRITIS; GASTROINTESTINAL DISEASE; GASTROINTESTINAL TOXICITY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; NERVE CELL; NONHUMAN; OSTEOARTHRITIS; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STOMACH ACID SECRETION; STOMACH INJURY; STOMACH ULCER; TREATMENT OUTCOME;

ANIMALS; ANTIOXIDANTS; GASTRIC MUCOSA; HUMANS; INTESTINAL MUCOSA; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 33750378814     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mog.0000245540.87784.75     Document Type: Review

References (66)

1. Flemström G, Isenberg JI. Gastroduodenal mucosal alkaline secretion and mucosal protection. News Physiol Sci 2001; 16:23-28.
2. Akiba Y, Furukawa O, Guth PH, et al. Cellular bicarbonate protects rat duodenal mucosa from acid-induced injury. J Clin Invest 2001; 108:1807-1816.
3. Pohle T, Brzozowski T, Becker JC, et al. Role of reactive oxygen metabolites in aspirin-induced gastric damage in humans: gastroprotection by vitamin C. Aliment Pharmacol Ther 2001; 15:677-687.
4. Grisham MB, Granger DN. Neutrophil-mediated mucosal injury: role of reactive oxygen metabolites. Dig Dis Sci 1988; 33:6S-15S.
5. Hiraishi H, Shimada T, Ivey KJ, Terano A. Role of antioxidant defenses against ethanol-induced damage in cultured rat gastric epithelial cells. J Pharmacol Exp Ther 1999; 289:103-109.
6. Zimmerman BJ, Grisham MB, Granger DN. Role of oxidants in ischemia/reperfusion-induced granulocyte infiltration. Am J Physiol Gastrointest Liver Physiol 1990; 258:G185-G190.
7. Matthews GM, Butler RN. Cellular mucosal defense during Helicobacter pylori infection: a review of the role of glutathione and the oxidative pentose pathway. Helicobacter 2005; 10:298-306.
8. Das D, Bandyopadhyay D, Bhattacharjee M, Banerjee RK. Hydroxyl radical is the major causative factor in stress-induced gastric ulceration. Free Radic Biol Med 1997; 23:8-18.
9. Choung RS, Talley NJ. Novel mechanisms in functional dyspepsia. World J Gastroenterol 2006; 12:673-677. An excellent recent editorial addressing the pathophysiology of functional dyspepsia, covering genetic factors, motility disturbances, infectious agents, and psychosocial abnormalities.
10. Lee KJ, Kim JH, Cho SW. Dyspeptic symptoms associated with hypersensitivity to gastric distension induced by duodenal acidification. J Gastroenterol Hepatol 2006; 21:515-520. Although functional dyspepsia is traditionally associated with motility disturbances, the authors tested the hypothesis that duodenal acidification lowers the threshold for duodenal distension. Their data supported their hypothesis that luminal acid sensitizes duodenal mechanoreception.
11. Lee KJ, Demarchi B, Demedts I, et al. A pilot study on duodenal acid exposure and its relationship to symptoms in functional dyspepsia with prominent nausea. Am J Gastroenterol 2004; 99:1765-1773.
12. Holzer P. Chemosensitive afferent nerves in the regulation of gastric blood flow and protection. Adv Exp Med Biol 1995; 371B:891-895.
13. Akiba Y, Kaunitz JD. Regulation of intracellular pH and blood flow in rat duodenal epithelium in vivo. Am J Physiol Gastrointest Liver Physiol 1999; 276:G293-G302.
14. ••]) is the first study to examine the role of ecto-carbonic anhydrases on duodenal acid absorption, with implications on mucosal defense and acid-sensing. This is also the first detailed study of duodenal carbonic anhydrase isoform expression.
15. + conversions.
16. Bhat YM, Bielefeldt K. Capsaicin receptor (TRPV1) and nonerosive reflux disease. Eur J Gastroenterol Hepatol 2006; 18:263-270. TRPV1 is strongly implicated as a subepithelial acid sensor in esophagus, possibly playing a role in heartburn, establishing an important clinical correlate.
17. Tanaka S, Chu S, Hirokawa M, et al. Direct measurement of acid permeation into rat oesophagus. Gut 2003; 52:775-783.
18. Domotor A, Peidl Z, Vincze A, et al. Immunohistochemical distribution of vanilloid receptor, calcitonin-gene related peptide and substance P in gastrointestinal mucosa of patients with different gastrointestinal disorders. Inflammopharmacology 2005; 13:161-177. Survey of the afferent elements implicated in clinical luminal acid sensing.
19. •].
20. Faussone-Pellegrini MS, Taddei A, Bizzoco E, et al. Distribution of the vanilloid (capsaicin) receptor type 1 in the human stomach. Histochem Cell Biol 2005; 124:61-68. Using three antibodies, the authors immunolocalized TRPV1 in rat stomach to the parietal cells and submucosal neuronal structures. Surprisingly, TRPV1 appeared to be present near mitochondria, where the authors hypothesized that it could play a role in the regulation of acid secretion.
21. Aihara E, Hayashi M, Sasaki Y, et al. Mechanisms underlying capsaicin-stimulated secretion in the stomach: comparison with mucosal acidification. J Pharmacol Exp Ther 2005; 315:423-432.
22. Kojima M, Hosoda H, Date Y, et al. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 1999; 402:656-660.
23. Tanaka-Shintani M, Watanabe M. Distribution of ghrelin-immunoreactive cells in human gastric mucosa: comparison with that of parietal cells. J Gastroenterol 2005; 40:345-349.
24. Dixit VD, Schaffer EM, Pyle RS, et al. Ghrelin inhibits leptin- and activation-induced proinflammatory cytokine expression by human monocytes and T cells. J Clin Invest 2004; 114:57-66.
25. Isomoto H, Ueno H, Nishi Y, et al. Circulating ghrelin levels in patients with various upper gastrointestinal diseases. Dig Dis Sci 2005; 50:833-838.
26. Isomoto H, Nishi Y, Ohnita K, et al. The relationship between plasma and gastric ghrelin levels and strain diversity in Helicobacter pylori virulence. Am J Gastroenterol 2005; 100:1425-1427.
27. Isomoto H, Ueno H, Nishi Y, et al. Impact of Helicobacter pylori infection on ghrelin and various neuroendocrine hormones in plasma. World J Gastroenterol 2005; 11:1644-1648.
28. Isomoto H, Ueno H, Saenko VA, et al. Impact of Helicobacter pylori infection on gastric and plasma ghrelin dynamics in humans. Am J Gastroenterol 2005; 100:1711-1720.
29. Sibilia V, Rindi G, Pagani F, et al. Ghrelin protects against ethanol-induced gastric ulcers in rats: studies on the mechanisms of action. Endocrinology 2003; 144:353-359.
30. Fukuhara S, Suzuki H, Masaoka T, et al. Enhanced ghrelin secretion in rats with cysteamine-induced duodenal ulcers. Am J Physiol Gastrointest Liver Physiol 2005; 289:G138-G145.
31. Iseri SO, Sener G, Yuksel M, et al. Ghrelin against alendronate-induced gastric damage in rats. J Endocrinol 2005; 187:399-406. Ghrelin treatment reversed effects of alendronate on rat gastric mucosa, including significant gastric damage, increased myeloperoxidase activity, collagen content, malondialdehyde, and luminal levels, and decreased glutathione levels.
32. Sibilia V, Torsello A, Pagani F, et al. Effects of hexarelin against acid-independent and acid-dependent ulcerogens in the rat. Peptides 2004; 25:2163-2170.
33. Ligumsky M, Klar A, Siguencia J, et al. Changes in reducing power profile of gastric juice in patients with active duodenal ulcer. Biomed Pharmacother 2005; 59:345-350.
34. McLean JA, Karadas F, Surai PF, et al. Lipid-soluble and water-soluble antioxidant activities of the avian intestinal mucosa at different sites along the intestinal tract. Comp Biochem Physiol B Biochem Mol Biol 2005; 141:366-372.
35. Derin N, Agac A, Bayram Z, et al. Effects of L-carnitine on neutrophil-mediated ischemia-reperfusion injury in rat stomach. Cell Biochem Funct 2005 (epub ahead of print). L-Carnitine treatment prior to ischemia significantly reduced both gastric injury and myeloperoxidase activity, a marker of neutrophil accumulation.
36. Dokmeci D, Akpolat M, Aydogdu N, et al. L-carnitine inhibits ethanol-induced gastric mucosal injury in rats. Pharmacol Rep 2005; 57:481-488.
37. Zanardo RC, Perretti M, Wallace JL. Annexin-1 is an endogenous gastroprotective factor against indomethacin-induced damage. Am J Physiol Gastrointest Liver Physiol 2005; 288:G481-G486.
38. Soll AH, Weinstein WM, Kurata J, McCarthy D. Nonsteroidal anti-inflammatory drugs and peptic ulcer disease. Ann Intern Med 1991; 114:307-319.
39. Adding LC, Agvald P, Andersson LI, et al. Direct gas measurements indicate that the novel cyclooxygenase inhibitor AZD3582 is an effective nitric oxide donor in vivo. Br J Pharmacol 2005; 145:679-687.
40. Berndt G, Grosser N, Hoogstraate J, Schroder H. AZD3582 increases heme oxygenase-1 expression and antioxidant activity in vascular endothelial and gastric mucosal cells. Eur J Pharm Sci 2005; 25:229-235. AZD3582 incubated with human endothelial cells increased expression of heme oxygenase-1 mRNA and protein whereas naproxen and rofecoxib did not. The heme oxygenase-1 metabolite bilirubin suppressed NADPH-dependent oxidative stress.
41. Schnitzer TJ, Kivitz AJ, Lipetz RS, et al. Comparison of the COX-inhibiting nitric oxide donator AZD3582 and rofecoxib in treating the signs and symptoms of osteoarthritis of the knee. Arthritis Rheum 2005; 53:827-837.
42. Wilder-Smith CH, Jonzon B, Fornstedt-Wallin B, et al. Dose-effect comparisons of the CINOD AZD3582 and naproxen on upper gastrointestinal tract mucosal injury in healthy subjects. Scand J Gastroenterol 2006; 41:264-273. Healthy volunteers given AZD3582 had significantly lower incidences of gastroduodenal toxicity compared with equimolar doses of naproxen.
43. Lohmander LS, McKeith D, Svensson O, et al. A randomised, placebo controlled, comparative trial of the gastrointestinal safety and efficacy of AZD3582 versus naproxen in osteoarthritis. Ann Rheum Dis 2005; 64:449-456.
44. Nagano Y, Matsui H, Muramatsu M, et al. Rebamipide significantly inhibits indomethacin-induced mitochondrial damage, lipid peroxidation, and apoptosis in gastric epithelial RGM-1 cells. Dig Dis Sci 2005; 50 (suppl 1):S76-S83. Rebamipide protects against indomethacin-induced damage by promoting mitochondrial membrane stability in gastric epithelial cells.
45. Hiratsuka T, Futagami S, Shindo T, et al. Rebamipide reduces indomethacin-induced gastric injury in mice via down-regulation of ICAM-1 expression. Dig Dis Sci 2005; 50 (suppl 1):S84-S89. Rebamipide downregulates intercellular adhesion molecule-1, which is a key molecule involved in neutrophil activation, thus protecting against indomethacin-induced gastric injury.
46. Naito Y, Kajikawa H, Mizushima K, et al. Rebamipide, a gastro-protective drug, inhibits indomethacin-induced apoptosis in cultured rat gastric mucosal cells: association with the inhibition of growth arrest and DNA damage-induced 45 alpha expression. Dig Dis Sci 2005; 50 (suppl 1):S104-S112.
47. Katada K, Yoshida N, Isozaki Y, et al. Prevention by rebamipide of acute reflux esophagitis in rats. Dig Dis Sci 2005; 50 (suppl 1):S97-S103. Rebamipide is useful in the prevention and treatment of reflux esophagitis through its antioxidant, antineutrophil, and anticytokine effects.
48. Harada N, Okajima K, Liu W. Rebamipide decreases the susceptibility of gastric mucosa to acid-induced injury in rats by inhibiting neutrophil activation. Dig Dis Sci 2005; 50 (suppl 1):S56-S62.
49. Sakurai K, Osaka T, Yamasaki K. Rebamipide reduces recurrence of experimental gastric ulcers: role of free radicals and neutrophils. Dig Dis Sci 2005; 50 (suppl 1):S90-S96. Rebamipide prevented the delayed effects of neutrophil accumulation and free-radical damage in acetic-acid-induced gastric ulcers at 60, 100, and 140 days, effectively preventing the recurrence of ulcers.
50. Miller TA. Protective effects of prostaglandins against gastric mucosal damage: current knowledge and proposed mechanisms. Am J Physiol Gastrointest Liver Physiol 1983; 245:G601-G623.
51. Murata H, Yabe Y, Tsuji S, et al. Gastro-protective agent rebamipide induces cyclooxygenase-2 (COX-2) in gastric epithelial cells. Dig Dis Sci 2005; 50 (suppl 1):S70-S75.
52. Watanabe T, Higuchi K, Taira K, et al. Rebamipide reduces delay in gastric ulcer healing in cyclooxygenase-2-deficient mice. Dig Dis Sci 2005; 50 (suppl 1):S63-S69.
53. Tarnawski A, Pai R, Chiou SK, et al. Rebamipide inhibits gastric cancer growth by targeting survivin and Aurora-B. Biochem Biophys Res Commun 2005; 19:207-212.
54. Vallböhmer D, Peters JH, Oh D, et al. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma. Surgery 2005; 138:701-706.
55. Kim JH, Choi SK, Choi SY, et al. Suppressive effect of astaxanthin isolated from the Xanthophyllomyces dendrorhous mutant on ethanol-induced gastric mucosal injury in rats. Biosci Biotechnol Biochem 2005; 69:1300-1305.
56. Kim JH, Kim YS, Song GG, et al. Protective effect of astaxanthin on naproxen-induced gastric antral ulceration in rats. Eur J Pharmacol 2005; 514:53-59.
57. Oh TY, Ahn GJ, Choi SM, et al. Increased susceptibility of ethanol-treated gastric mucosa to naproxen and its inhibition by DA-9601, an Artemisia asiatica extract. World J Gastroenterol 2005; 11:7450-7456.
58. Molina V, Carbajal D, Arruzazabala L, Mas R. Therapeutic effect of D-002 (abexol) on gastric ulcer induced experimentally in rats. J Med Food 2005; 8:59-62.
59. Freire RS, Morais SM, Catunda-Junior FE, Pinheiro DC. Synthesis and antioxidant, anti-inflammatory and gastroprotector activities of anethole and related compounds. Bioorg Med Chem 2005; 13:4353-4358.
60. Kanter M, Demir H, Karakaya C, Ozbek H. Gastroprotective activity of Nigella sativa L oil and its constituent, thymoquinone against acute alcohol-induced gastric mucosal injury in rats. World J Gastroenterol 2005; 11:6662-6666.
61. Kabasakal L, Sener G, Cetinel S, et al. Burn-induced oxidative injury of the gut is ameliorated by the leukotriene receptor blocker montelukast. Prostaglandins Leukot Essent Fatty Acids 2005; 72:431-440.
62. 2 levels or indomethacin-induced cyclooxygenase-2 expression.
63. Mera R, Fontham ET, Bravo LE, et al. Long term follow up of patients treated for Helicobacter pylori infection. Gut 2005; 54:1536-1540.
64. Ghosh S, May MJ, Kopp EB. NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 1998; 16:225-260.
65. O'Toole D, Abdel-Latif MM, Long A, et al. Low pH and Helicobacter pylori increase nuclear factor kappa B binding in gastric epithelial cells: a common pathway for epithelial cell injury? J Cell Biochem 2005; 96:589-598. NF-κB activity is upregulated in the presence of both H. pylori and low pH, suggesting a common pathway for mucosal injury.
66. Oh TY, Yeo M, Han SU, et al. Synergism of Helicobacter pylori infection and stress on the augmentation of gastric mucosal damage and its prevention with alpha-tocopherol. Free Radic Biol Med 2005; 38:1447-1457.